FY2025 EPS Estimate for Kura Oncology Lowered by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Management reduced their FY2025 EPS estimates for Kura Oncology in a research report issued on Monday, January 12th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($2.90) per share for the year, down from their prior forecast of ($2.87). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s Q4 2025 earnings at ($0.65) EPS.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million.

A number of other equities research analysts have also recently commented on KURA. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, October 20th. Leerink Partners set a $20.00 target price on Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday. UBS Group boosted their target price on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Finally, Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $8.91 on Wednesday. The firm has a fifty day moving average of $10.66 and a two-hundred day moving average of $8.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.12 and a current ratio of 5.12. The stock has a market capitalization of $775.35 million, a price-to-earnings ratio of -3.59 and a beta of 0.25. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $12.49.

Insider Buying and Selling

In other news, insider Francis Burrows sold 23,726 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $9.78, for a total transaction of $232,040.28. Following the sale, the insider owned 33,735 shares of the company’s stock, valued at $329,928.30. This trade represents a 41.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,539 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $50,746.02. Following the completion of the transaction, the senior vice president owned 130,257 shares of the company’s stock, valued at $1,456,273.26. This represents a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 68,343 shares of company stock valued at $730,858. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its position in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after acquiring an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period. Pallas Capital Advisors LLC lifted its holdings in shares of Kura Oncology by 32.2% in the second quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock valued at $77,000 after purchasing an additional 3,241 shares in the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Kura Oncology in the second quarter valued at about $80,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.